30 shares by overseas institutions pile research, pharmaceutical and biological fields have 4.

According to the pharmaceutical network industry dynamics, a total of 170 companies were investigated in the last 10 days (July 6 to July 17)In terms of the types of research institutions, the number of securities companies surveyed 149, the largest proportion of the fund companies, followed by the research, reached 107, overseas institutions to visit a total of 30 listed companiesAmong them, 30 overseas research units of the industry classification, the main focus on pharmaceutical biology, light industry manufacturing, automotive and other fieldsAmong them, there are 4 pharmaceutical organisms, respectively, international medicine, Shanghai Leishi, American Year health, yam medicine auxiliaryNumber of international medical institutions overseas: 30 overseas institutions in the research list, the number of international medical participation in the survey of overseas institutions, it can be seen that the high degree of attentionAt present, the total market value of international medicine is 11.14 billion yuan, and the average market value of the medical industry to which it belongs is 24.91 billion yuanInternational Medicine recently disclosed the 2020 half-year results forecast, the company attributed to the shareholders of listed companies in the first half of the net profit is expected to lose 355 million yuan - 335 million yuanAccording to the first quarter of 2020, the company's operating income was RMB275.18 million, up 24.96 percent year-on-year, and the net profit attributable to shareholders of listed companies was about RMB189.43 millionInternational Medicine said that in March after the resumption of work, the company's medical services business quickly resumedAt present, Xi'an International Medical High-tech Hospital bed use has reached full operating state, Xi'an International Medical Center Hospital in the number of hospitals continue to increase, with the continuous use of medical beds, the company's medical business scale will continue to growData show that international medicine is a large health medical services and modern medical technology conversion applications of the company, its medical industry accounted for 98.88 percent of operating incomeShanghai Leiser overseas institutions: 1 Shanghai Leishi currently has a total market value of 63.97 billion, the pharmaceutical manufacturing industry to which it belongs has an average market value of 21.81 billionOn the evening of July 13, Shanghai Leishi issued a half-year results forecast for 2020, with a net profit of 695 million yuan to 745 million yuan attributable to shareholders of listed companies, an increase of 68% to 80% over the same period last yearIn response to the reasons for the substantial increase in interim results, the announcement showed that the main reason is that during the reporting period, the company's major asset restructuring target GDS 45% equity transfer completed, the company enjoys the GDS equity transfer after the investment ratio of 45% calculatedAt the same time, during the reporting period, the company's main business development is stable, the company further enhanced management efficiency and operating level, and achieved good results, the January-June 2020 period of expenses and expenses incurred losses from the same period last year decreased, on the positive impact of the growth in the interim resultsData show that Shanghai Laishi is the domestic leading blood products production enterprises, the main business for the production and sale of blood products, the main products for human hemoglobin, static injection of human immunoglobulin, specific immunoglobulin, clotting factor productsNumber of U.S Annual Health Overseas Institutions: 5 U.S Annual Health currently has a total market value of 63.93 billion yuan As a leader in the private medical examination market, the development and performance of the continuous nationalized layout of health in the United States has attracted much attention from the market The company forecasts a loss of 650-850 million yuan in the first half of 2020 The reason is that stores were not open in the first half of the year due to the special period Data show that The New Year's Health is a health check-up as the core, health counseling, health assessment, health intervention in one of the domestic professional health check-up and medical services The number of overseas institutions of Yamhe pharmaceutical supplement: 1 Yamhe medicine supplement currently has a total market value of 4.526 billion Its business for the development, production and sales of pharmaceutical accessories In the first quarter of 2020, the Company achieved operating income of RMB125 million, up 8.50% YoY, and net profit attributable to shareholders of listed companies was RMB238.5 billion, up 22.60% YoY